Abstract: Compositions and methods for treating thrombosis, inflammation, and atherosclerosis by administration of a compound that binds to KRIT1 to inhibit binding with HEG1.

Abstract: Antibodies against CD25 engineered with dysfunctional constant regions used to bind T regulatory cells to activate integrin to inhibit immune responses and for treatment of autoimmune diseases such as systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease, in addition to transplantation rejection. The invention demonstrates that treatment of CD4+ T cells with CD25 antibody results in rapid activation of multiple integrins as measured by soluble ligand binding.

Abstract: The present invention is directed to novel compounds that are able to inhibit the interaction of paxillin or its paralogues, including leupaxin or Hic-5, with alpha.4 integrin or its binding partners that regulate signaling events downstream of the paxillin-.alpha.4 interaction. The present invention further relates to methods for therapeutic use of such compounds and pharmaceutical compositions of such compounds for the treatment of a disease or condition.

Abstract: The specific molecular basis of the interaction between talin and integrin ?3 has been defined. This specific interaction provides a new therapeutic target; agents that can disrupt this specific interaction should be useful therapeutic agents for a number of significant diseases and conditions including inflammation, heart disease, including myocardial infarction, and tumor metastasis. The present invention includes a chimeric peptide that has high affinity for talin, muteins of talin and integrin ?3 as well as screening methods for agents that can disrupt the interaction between talin and integrin ?3.

Abstract: The present invention is directed to novel compounds that are able to inhibit the interaction of paxillin or its paralogues, including leupaxin or Hic-5, with alpha.4 integrin or its binding partners that regulate signaling events downstream of the paxillin-alpha.4 interaction. The present invention further relates to methods for therapeutic use of such compounds and pharmaceutical compositions of such compounds for the treatment of a disease or condition.

Abstract: The specific molecular basis of the interaction between talin and integrin ?3 has been defined. This specific interaction provides a new therapeutic target; agents that can disrupt this specific interaction should be useful therapeutic agents for a number of significant diseases and conditions including inflammation, heart disease, including myocardial infarction, and tumor metastasis. The present invention includes a chimeric peptide that has high affinity for talin, muteins of talin and integrin ?3 as well as screening methods for agents that can disrupt the interaction between talin and integrin ?3.

Abstract: A purified compound and its pharmaceutically acceptable salt that inhibits the binding between the integrin intracellular or cytoplasmic tail polypeptide and Paxillin, a pharmaceutical composition containing that compound or salt and a method of treating a biological function in an animal using that compound or salt are disclosed. The purified compound corresponds in structure to Formula I, wherein W1 and W2, X1, X2 and X3 and Y are defined within.

Abstract: An apparatus for controlling output signals from an amplifier when changing state; the amplifier having input loci, output loci and a state locus, and changing state in response to a state controlling signal received at the state locus; includes: (a) a state sensing circuit coupled with the state locus that provides a state signal in response to the state controlling signal; (b) an input level unit coupled with the state sensing circuit and with a selected input locus, and setting a first input signal level at the selected input locus when the amplifier changes from a first state to a second state; and (c) an output level unit coupled with the state sensing circuit and with a selected output locus, and setting a first output signal level at the selected output locus when the amplifier changes from the first state to the second state.

Abstract: An apparatus for controlling output signals from an amplifier when changing state; the amplifier having input loci, output loci and a state locus, and changing state in response to a state controlling signal received at the state locus; includes: (a) a state sensing circuit coupled with the state locus that provides a state signal in response to the state controlling signal; (b) an input level unit coupled with the state sensing circuit and with a selected input locus, and setting a first input signal level at the selected input locus when the amplifier changes from a first state to a second state; and (c) an output level unit coupled with the state sensing circuit and with a selected output locus, and setting a first output signal level at the selected output locus when the amplifier changes from the first state to the second state.

Abstract: Diagnostic systems, methods, polypeptides and antibodies for detecting the presence of C-terminal hGPIIb fragment of the platelet receptor GPIIb-IIIa in a body fluid sample are disclosed.

Abstract: .beta..sub.3 integrin subunit specific polypeptides, cDNAs which encode these polypeptides and methods of producing these polypeptides are provided.

Abstract: .beta..sub.3 integrin subunit specific polypeptides, cDNAs which encode these polypeptides and methods of producing these polypeptides are provided.